FDA Drug Safety Communication: Revlimid
The U.S. Food and Drug Administration (FDA) is informing the public that we are aware of results from clinical trials conducted inside and outside the United States that found that patients treated with Revlimid ( lenalidomide ) may be at an increased risk of developing new types of cancer compared to patients who did not take the drug. FDA is currently reviewing all available information on this potential risk and will communicate any new recommendations once it has completed its review. At this time, FDA recommends that patients continue their Revlimid treatment as prescribed by their...
New Hope for Multiple Myeloma Patients
While there is no cure for multiple myeloma, a form of blood cancer, new therapy offers hope for keeping the disease from progressing. When used as a maintenance or ongoing therapy, Revlimid (lenalidomide) delays the progression of multiple myeloma and improves overall survival of newly diagnosed patients who have had a stem-cell transplant.